US.BIIB · Biogen

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.5924287366145493,
        "turnoverUsdM": 324.98731331,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BIIB",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 184.6186,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 7.2,
      "take_profit_price": 213.6182,
      "target_multiplier": 1.9,
      "technical_strength": 1.63,
      "take_profit_percent": 7.4
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 7.184857473229099,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 55.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 47.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 203.5105,
    "ma50": 197.1758,
    "close": 198.91,
    "prevClose": 200.36,
    "avgVolume20": 1297942,
    "volumeRatio": 1.26,
    "changePercent": -0.72
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": -0.05163540327856386,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 1.2936601317539749,
      "ret_points": 0,
      "vol_points": 4,
      "range_ratio": 0.7665188083795131,
      "volat_points": 0,
      "day_range_pct": 0.025136996631642452,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 55.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 56,
        "contribution": 2.8
      },
      {
        "raw": 6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 9.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 61.33,
        "contribution": 9.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.9,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 59,
        "contribution": 5.9
      },
      {
        "raw": 17.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 59.33,
        "contribution": 17.8
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 47.7,
    "details": [
      "基本面分析總分: 2.8/5分",
      "資金流分析總分: 6/20分",
      "市場環境分析總分: 9.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.9/10分",
      "技術信號分析總分: 17.8/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.8,
      "資金流": 6,
      "市場環境": 9.2,
      "情緒分析": 4,
      "技術信號": 17.8,
      "風險管理": 5.9
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.4,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 324.98731331,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BIIB",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.9
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 720.9690033500002,
                "ma50": 713.79420164,
                "name": "QQQ",
                "close": 723.17999,
                "points": 2
              },
              "spy": {
                "ma20": 742.33551,
                "ma50": 740.3722033000001,
                "name": "SPY",
                "close": 751.71002,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.5924287366145493,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140833226,
                "url": "https://finnhub.io/api/news?id=87a299e9a577b4c947d1633e3db6e984a23d7b99ceb98ac5c64a949ffbb1ee28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783440605,
                "headline": "Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again"
              },
              {
                "id": 140813366,
                "url": "https://finnhub.io/api/news?id=cb7628a5eb59c83089d360adea3cf8de59497534cd4b7268a622d945dc897161",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]",
                "category": "company",
                "datetime": 1783256354,
                "headline": "Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now"
              },
              {
                "id": 140805970,
                "url": "https://finnhub.io/api/news?id=75ba0c1561046e54f059b8e03c06190d1e9f2b1b0aa1de1a4668ec084aed3fa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "This could be a key move for future growth.",
                "category": "company",
                "datetime": 1783153320,
                "headline": "Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors."
              },
              {
                "id": 140796522,
                "url": "https://finnhub.io/api/news?id=f96e73508ef4c1871f05c82d55aa25e3236bfd3b6f05e974e87a8457d2b914ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Jay Woods recommended investing in the BioTech ETF and Biogen in particular within the ETF.",
                "category": "company",
                "datetime": 1783036407,
                "headline": "BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers"
              },
              {
                "id": 140788353,
                "url": "https://finnhub.io/api/news?id=4627183fd380a8cc71c75dc6c5b57184f4f06a2a8a9ba94b186e54a86b7465b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed picture rather than a clear bargain or clear overvaluation, investors are weighing how much of the recent Alzheimer’s and immunology news is already reflected in the price. Over the last 12 months, Biogen has returned 57.5%, which puts a spotlight on whether today’s share price still offers an attractive entry point or mainly reflects recent optimism. On the upside,...",
                "category": "company",
                "datetime": 1782976490,
                "headline": "Is Biogen (BIIB) Priced Near Fair Value After Its 57% Run?"
              },
              {
                "id": 140786609,
                "url": "https://finnhub.io/api/news?id=0c6f72604f707ca77cc99f0892a2b36910dedb9a37f0dd8847ea5b813b5f395f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NasdaqGS:BIIB) plans to present new investigational data from its Alzheimer’s portfolio at AAIC 2026. The company will share detailed Phase 2 CELIA results for diranersen, a tau-targeting therapy. Biogen will also present real-world evidence on subcutaneous lecanemab, including usage patterns and long-term outcomes. For investors tracking Biogen, the AAIC 2026 agenda centers on two core Alzheimer’s assets that are central to the company’s neurodegeneration focus. Diranersen targets...",
                "category": "company",
                "datetime": 1782955123,
                "headline": "Biogen (BIIB) To Share New Alzheimer’s Data At AAIC 2026"
              },
              {
                "id": 140763996,
                "url": "https://finnhub.io/api/news?id=f241264e1ae813d3d1334adca34d4c30f747d2ac81b88d7e5865f733236d5d8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.",
                "category": "company",
                "datetime": 1782745800,
                "headline": "Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs"
              },
              {
                "id": 140761798,
                "url": "https://finnhub.io/api/news?id=99d57115c212434a7b057957cce12094854beb5df466622b622f33c7fe8e0a84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782734820,
                "headline": "Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?"
              }
            ],
            "raw_source": [
              {
                "id": 140852407,
                "url": "https://finnhub.io/api/news?id=93c73432a1e7673d15bfa810df331e53f5a7211080e7837c9bb9d89d1c99a5a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with disease severity and clinical manifestations varying considerably among patients. Despite significant advances in understanding its pathophysiology, SLE remains incurable, and current treatment strategies primarily focus on controlling disease activity, achieving remission or low disease activity, preventing irreversible organ damage, minimizing flares, and improving patients'",
                "category": "company",
                "datetime": 1783607460,
                "headline": "Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight"
              },
              {
                "id": 140854879,
                "url": "https://finnhub.io/api/news?id=ce65ce2b089fd2cf93623cc7ccd97daa63d0593a026508e2b80549b26b9c0fb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.",
                "category": "company",
                "datetime": 1783600099,
                "headline": "Biogen's Q2 2026 Earnings: What to Expect"
              },
              {
                "id": 140850088,
                "url": "https://finnhub.io/api/news?id=e847fedf43124783edcb753cd3d81470a44d61c96f4b63d34a1e67601b823d3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "On July 8, 2026, Moderna, Inc. appointed veteran financial executive Michael McDonnell, former Biogen CFO, to its Board of Directors and Audit Committee, while a federal advisory panel previously backed approval of the company’s first-of-its-kind mRNA influenza vaccine. Together with new programs in autoimmune disease, ovarian cancer and an AI-enabled research platform, these developments highlight Moderna’s push to broaden its mRNA franchise beyond COVID-19 and seasonal respiratory...",
                "category": "company",
                "datetime": 1783591935,
                "headline": "Will New Board Appointment And mRNA Flu Progress Change Moderna's (MRNA) Pipeline Diversification Narrative?"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140853032,
                "url": "https://finnhub.io/api/news?id=4bb3e9d835d280ecf692c6bf349520f28767a8c3e8cc28198384b66c3201336e",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $224 to $222.",
                "category": "company",
                "datetime": 1783513509,
                "headline": "Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $222"
              },
              {
                "id": 140842286,
                "url": "https://finnhub.io/api/news?id=7f70607135913a747248cddc872c58baa0448ad7a4f6f85e64e0d2058870d996",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "A July filing shows that Representative Maria Elvira Salazar reported a purchase in Brookfield Renewable (NYSE:BEP), valued between $50,008 and $225,000. The transaction date is listed as June 4, 2026, with the report",
                "category": "company",
                "datetime": 1783508412,
                "headline": "Congressional Trading Report: Rep. Maria Elvira Salazar Bought Over $50K In Brookfield Renewable Stock"
              },
              {
                "id": 140839747,
                "url": "https://finnhub.io/api/news?id=330deea0f937ba4fc68084a259ccf67f7595ac07a1ae24c96525a42b66911ac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell ...",
                "category": "company",
                "datetime": 1783508400,
                "headline": "Moderna Appoints Michael McDonnell to Board of Directors"
              },
              {
                "id": 140833225,
                "url": "https://finnhub.io/api/news?id=2c21c0d4441f282ca0e4101ecb878317ea4a0bee0ef2c4db4c83a4b62cd67c1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.",
                "category": "company",
                "datetime": 1783441680,
                "headline": "IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study"
              },
              {
                "id": 140833226,
                "url": "https://finnhub.io/api/news?id=87a299e9a577b4c947d1633e3db6e984a23d7b99ceb98ac5c64a949ffbb1ee28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783440605,
                "headline": "Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again"
              },
              {
                "id": 140833326,
                "url": "https://finnhub.io/api/news?id=351483ad142a44454c749bbb1cc6bd5f4f8fc0f182938055e907b2088de11551",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $227 to $242.",
                "category": "company",
                "datetime": 1783424303,
                "headline": "RBC Capital Maintains Outperform on Biogen, Raises Price Target to $242"
              },
              {
                "id": 140830203,
                "url": "https://finnhub.io/api/news?id=75014b57a5eaea585df8853c5a378ed4fa238d1cdac808c53590a990dc26c001",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.",
                "category": "company",
                "datetime": 1783417140,
                "headline": "Vertex to acquire Crinetics in $10B foray into endocrine disease drugs"
              },
              {
                "id": 140823559,
                "url": "https://finnhub.io/api/news?id=5a144f07bedba347af467925be73da106be1e89722253a4d07e63d464f1aecad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.",
                "category": "company",
                "datetime": 1783361040,
                "headline": "3 Healthcare ETFs to Own in a Choppy Stock Market"
              },
              {
                "id": 140813366,
                "url": "https://finnhub.io/api/news?id=cb7628a5eb59c83089d360adea3cf8de59497534cd4b7268a622d945dc897161",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]",
                "category": "company",
                "datetime": 1783256354,
                "headline": "Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now"
              },
              {
                "id": 140805970,
                "url": "https://finnhub.io/api/news?id=75ba0c1561046e54f059b8e03c06190d1e9f2b1b0aa1de1a4668ec084aed3fa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "This could be a key move for future growth.",
                "category": "company",
                "datetime": 1783153320,
                "headline": "Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors."
              },
              {
                "id": 140796522,
                "url": "https://finnhub.io/api/news?id=f96e73508ef4c1871f05c82d55aa25e3236bfd3b6f05e974e87a8457d2b914ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Jay Woods recommended investing in the BioTech ETF and Biogen in particular within the ETF.",
                "category": "company",
                "datetime": 1783036407,
                "headline": "BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers"
              },
              {
                "id": 140789064,
                "url": "https://finnhub.io/api/news?id=ea6d4d8fa618a47292b12f27fc95b4520370ef21c3e722e2dd4f8fc3240d5d4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.",
                "category": "company",
                "datetime": 1782984744,
                "headline": "1 S&P 500 Stock with Promising Prospects and 2 We Question"
              },
              {
                "id": 140788353,
                "url": "https://finnhub.io/api/news?id=4627183fd380a8cc71c75dc6c5b57184f4f06a2a8a9ba94b186e54a86b7465b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed picture rather than a clear bargain or clear overvaluation, investors are weighing how much of the recent Alzheimer’s and immunology news is already reflected in the price. Over the last 12 months, Biogen has returned 57.5%, which puts a spotlight on whether today’s share price still offers an attractive entry point or mainly reflects recent optimism. On the upside,...",
                "category": "company",
                "datetime": 1782976490,
                "headline": "Is Biogen (BIIB) Priced Near Fair Value After Its 57% Run?"
              },
              {
                "id": 140786609,
                "url": "https://finnhub.io/api/news?id=0c6f72604f707ca77cc99f0892a2b36910dedb9a37f0dd8847ea5b813b5f395f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NasdaqGS:BIIB) plans to present new investigational data from its Alzheimer’s portfolio at AAIC 2026. The company will share detailed Phase 2 CELIA results for diranersen, a tau-targeting therapy. Biogen will also present real-world evidence on subcutaneous lecanemab, including usage patterns and long-term outcomes. For investors tracking Biogen, the AAIC 2026 agenda centers on two core Alzheimer’s assets that are central to the company’s neurodegeneration focus. Diranersen targets...",
                "category": "company",
                "datetime": 1782955123,
                "headline": "Biogen (BIIB) To Share New Alzheimer’s Data At AAIC 2026"
              },
              {
                "id": 140785714,
                "url": "https://finnhub.io/api/news?id=6dc06718c1b7f05fded70240eb3922426e764506b9264330de52d189ad9b31ef",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a",
                "category": "company",
                "datetime": 1782923221,
                "headline": "Biogen Expects $164M Q2 2026 And $290M-$320M Q3 2026 IPR&D And Milestone Charges, Impacting Earnings By $0.95 And $1.75–$1.95 Per Share, Respectively"
              },
              {
                "id": 140780654,
                "url": "https://finnhub.io/api/news?id=1bd01f8e61ef51ebcb51cb5b0359bbb686d74196259eb0aebb6161b83b544b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.",
                "category": "company",
                "datetime": 1782911040,
                "headline": "Amgen or Biogen: Which Biotech Stock Appears Better Poised?"
              },
              {
                "id": 140778902,
                "url": "https://finnhub.io/api/news?id=36ae3ddf6ce459c2e6edb47b311ce5c545f5cb8792df28ebf96d6ed9ee90efb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "INCHEON, Korea, July 01, 2026--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 2025.",
                "category": "company",
                "datetime": 1782903600,
                "headline": "Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow"
              },
              {
                "id": 140771665,
                "url": "https://finnhub.io/api/news?id=8733763cfea3199fcae1f691f8e26460883bbd0ad583e34beba2ab050714d917",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.",
                "category": "company",
                "datetime": 1782810480,
                "headline": "New Strong Sell Stocks for June 30th"
              },
              {
                "id": 140763996,
                "url": "https://finnhub.io/api/news?id=f241264e1ae813d3d1334adca34d4c30f747d2ac81b88d7e5865f733236d5d8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.",
                "category": "company",
                "datetime": 1782745800,
                "headline": "Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs"
              },
              {
                "id": 140761798,
                "url": "https://finnhub.io/api/news?id=99d57115c212434a7b057957cce12094854beb5df466622b622f33c7fe8e0a84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782734820,
                "headline": "Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?"
              },
              {
                "id": 140760964,
                "url": "https://finnhub.io/api/news?id=b2afb749a7e570b0055be22375ca21f1e31a35a77b363e1dc8b609c955074afc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.",
                "category": "company",
                "datetime": 1782733369,
                "headline": "Biogen trims Apellis pipeline and R&D team after $5.6bn takeover"
              },
              {
                "id": 140772579,
                "url": "https://finnhub.io/api/news?id=1d609d0c19b237f1022a11a9c80ade78bdac5c93022f1f88ed7c11c13a77b8bd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/29/Biogen-World-Headquarters-At-225-Binney-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key priorities. PT increased to $256.",
                "category": "company",
                "datetime": 1782732451,
                "headline": "Biogen: Key Takeaways From Needham’s Meeting With Top Management"
              },
              {
                "id": 140760965,
                "url": "https://finnhub.io/api/news?id=0e12411714cc3b0fa125847d1437c9ba63522338a3c7df8e3c65a803b08fadd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced in May 2026Lecanemab presentations will highlight emerging data on subcutaneous administration and real-world use, including practical treatment considerations, at-home administration, three-year LEADER data, maintenance dosing and patient experienceAdvances across Biogen’s Alzhei",
                "category": "company",
                "datetime": 1782730740,
                "headline": "Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen"
              },
              {
                "id": 140762076,
                "url": "https://finnhub.io/api/news?id=daf8f48d5b31a92c23d93309085cb937926bf8de723bfa65bffbfd4dff46c9ba",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced",
                "category": "company",
                "datetime": 1782716517,
                "headline": "Biogen To Present New Data Across Alzheimer’s Disease Portfolio At AAIC 2026, Presentations To Include Data From Phase 2 CELIA Study Evaluating Diranersen, And New Analyses From Studies Of LEQEMBI"
              },
              {
                "id": 140762077,
                "url": "https://finnhub.io/api/news?id=ca6fb468047e4b7d80514572e9a244260011d013b1726a33fb48d63e746b0236",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Needham  analyst Ami Fadia   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $255 to $256.",
                "category": "company",
                "datetime": 1782713301,
                "headline": "Needham Maintains Buy on Biogen, Raises Price Target to $256"
              },
              {
                "id": 140741673,
                "url": "https://finnhub.io/api/news?id=43a600fb2ad5438f2f1771c843af456157c82cdfd3013de338867fff4ee08344",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth signals, including the $1 billion purchase of RayThera Inc., an FDA Breakthrough Therapy tag for its drug candidate Salanersen, and a recent analyst upgrade.",
                "category": "company",
                "datetime": 1782511705,
                "headline": "Why Biogen (BIIB) Stock Is Up Today"
              },
              {
                "id": 140737991,
                "url": "https://finnhub.io/api/news?id=4f1f92e9bfd556033ca1e9a7a947069be8194bd99d29c4f03bd80a254adeb6e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Lilly, AbbVie and J&J extend winning streaks.",
                "category": "company",
                "datetime": 1782496164,
                "headline": "Lilly, J&J and AbbVie Hit New Highs"
              },
              {
                "id": 140737291,
                "url": "https://finnhub.io/api/news?id=f967565bde51a202a27c29a0137a0c215d2512f7031b456cec9015d4e7b99a56",
                "image": "https://image.cnbcfm.com/api/v1/image/108222303-1762434766877-gettyimages-2235744008-CANADA_BIOMANUFACTURING.jpeg?v=1782492668&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1782478763,
                "headline": "Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more"
              },
              {
                "id": 140735458,
                "url": "https://finnhub.io/api/news?id=2e9b468085e3e52dd66253a98be2f9d262c6eac29c83f8fa3ac4282dfe26b889",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.",
                "category": "company",
                "datetime": 1782476400,
                "headline": "Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?"
              },
              {
                "id": 140724703,
                "url": "https://finnhub.io/api/news?id=351b3eb19e715a16d21f59dd642061c9d64d6f75ffe01be0818f08d68b71cae8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Axtria Inc., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme \"Industrializing Intelligence: The Agentic Enterprise.\" More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed.",
                "category": "company",
                "datetime": 1782389700,
                "headline": "Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI"
              },
              {
                "id": 140705774,
                "url": "https://finnhub.io/api/news?id=cd09cb16caa295cab5162b00185ad49078b0906ad5962d5c8eae82875ea48e65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season.",
                "category": "company",
                "datetime": 1782239086,
                "headline": "Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)"
              },
              {
                "id": 140693916,
                "url": "https://finnhub.io/api/news?id=04e269265cac7427175c0982f245bba6370b6072bbff05dc15f7239bd8257dd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune and dermatological disorders. The introduction of novel targeted therapies such as Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), and others, and biologi",
                "category": "company",
                "datetime": 1782147600,
                "headline": "Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight"
              },
              {
                "id": 140675161,
                "url": "https://finnhub.io/api/news?id=5444a5704726fc09eac78e6800a2e706e481fee5066427554fafe21bded43966",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a recent move in its share price, with the stock closing at US$196.58. That level sits against a backdrop of mixed short and longer term returns. See our latest analysis for Biogen. Short term momentum for Biogen looks softer, with the 1 day and 7 day share price returns both slightly negative, while the 1 month and year to date share price returns remain positive and the 1 year total shareholder return is...",
                "category": "company",
                "datetime": 1781917830,
                "headline": "Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative"
              },
              {
                "id": 140683227,
                "url": "https://finnhub.io/api/news?id=c4d90fdf5df9ffdb21df7b0ae459abafe14b693d50daf425ed18dce68642d069",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.",
                "category": "company",
                "datetime": 1781862498,
                "headline": "Biogen to acquire RayThera for up to $1bn"
              },
              {
                "id": 140664069,
                "url": "https://finnhub.io/api/news?id=3c4ab0eb3c02d7f757af9dafaa3cd12d4785b7595220d82dbba28bfc1f163a1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the Sta",
                "category": "company",
                "datetime": 1781804098,
                "headline": "Sector Update: Healthcare Stocks Decline Thursday Afternoon"
              },
              {
                "id": 140663082,
                "url": "https://finnhub.io/api/news?id=0d3c383fc254c63da01b9afeb83e08b2ed41a726c2714354ca3d4a7baf2ce06f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.",
                "category": "company",
                "datetime": 1781790660,
                "headline": "Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout"
              },
              {
                "id": 140662630,
                "url": "https://finnhub.io/api/news?id=a308f07cc8840dc41c59557eacf1974c575612bff8d87163e0a7f379b98bab78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer",
                "category": "company",
                "datetime": 1781790030,
                "headline": "Biogen acquires RayThera in deal worth up to $1 billion"
              },
              {
                "id": 140663266,
                "url": "https://finnhub.io/api/news?id=d00d9cd463f61ee8d99f9f19eef65db1aecb7d28e9ee66982ed58d39ecc965d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.",
                "category": "company",
                "datetime": 1781781120,
                "headline": "Biogen adds more immune drugs in $1B buyout of secretive startup Raythera"
              },
              {
                "id": 140666487,
                "url": "https://finnhub.io/api/news?id=0f49d541748b7603f54de0e98a439f2ea59cb29deac8d88d4365cd90654d2863",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/18/MA-Businessman-Handshake.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.",
                "category": "company",
                "datetime": 1781780835,
                "headline": "Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline"
              },
              {
                "id": 140662111,
                "url": "https://finnhub.io/api/news?id=b5c5239c0ed38bc49ae306c31f0dc5cd40dbe1d605029f21c92b0ad1ea749b8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 bill",
                "category": "company",
                "datetime": 1781779192,
                "headline": "Biogen to Acquire RayThera in Up to $1 Billion Deal to Expand Immunology Pipeline"
              },
              {
                "id": 140663769,
                "url": "https://finnhub.io/api/news?id=b06dc19185b2b6e376d18d3e57d7e32f0a1a511dd282286176de0b3c131e5f4a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/18/Riverview--Usa---October-4--2021-Progres.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.",
                "category": "company",
                "datetime": 1781778698,
                "headline": "Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday"
              },
              {
                "id": 140666489,
                "url": "https://finnhub.io/api/news?id=2541c83446bfb1d49348e492597852befcd7e363bd053ce050e7064fcaf8e56c",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $206 to $224.",
                "category": "company",
                "datetime": 1781769980,
                "headline": "Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $224"
              },
              {
                "id": 140659173,
                "url": "https://finnhub.io/api/news?id=43a6d1b35598bf3df082d513c1f4599b34e2d43e79d3390b2b432fc50f6d4c72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes.",
                "category": "company",
                "datetime": 1781741024,
                "headline": "BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal"
              },
              {
                "id": 140658378,
                "url": "https://finnhub.io/api/news?id=e7e893df2521305cd7e52d726cb34eb913faaf6cb22940def3835608af9c7fd6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 developmentCAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire RayThera Inc. for up to $1 billion, consi",
                "category": "company",
                "datetime": 1781737140,
                "headline": "Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc."
              },
              {
                "id": 140649661,
                "url": "https://finnhub.io/api/news?id=2b7353eacd4b6269e7fef5b9baa8791c221ae9fb262d39febad1d87e8d72bec3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part of a previously signed agreement, it stated. Register for our weekly newsletter HERE “We are […] The post Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1781648297,
                "headline": "Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease"
              },
              {
                "id": 140645112,
                "url": "https://finnhub.io/api/news?id=14abf5df2f33898070e22e98c656d121db1a72a098f70fbe575f1cedb534e7f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Canada Inc. is disappointed that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYCLARYS™ (omaveloxolone) have concluded without reaching an agreement.",
                "category": "company",
                "datetime": 1781615100,
                "headline": "Biogen Canada disappointed by outcome of pan-Canadian Pharmaceutical Alliance negotiations for SKYCLARYS™"
              },
              {
                "id": 140639866,
                "url": "https://finnhub.io/api/news?id=d3a1905c89095da9629b90b39f4f7b44033303457649eaf5b4330074aa37d9cf",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Mizuho  analyst Salim Syed   maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $236 to $221.",
                "category": "company",
                "datetime": 1781529603,
                "headline": "Mizuho Maintains Outperform on Biogen, Lowers Price Target to $221"
              },
              {
                "id": 140636820,
                "url": "https://finnhub.io/api/news?id=08fe62b48190a976301cf3684ee7b9c14592a49543e0a68de96c3c4a612297b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.",
                "category": "company",
                "datetime": 1781523127,
                "headline": "3 Overrated  Stocks Walking a Fine Line"
              },
              {
                "id": 140605419,
                "url": "https://finnhub.io/api/news?id=6ae34439347dfcb800796f07e81dfd285623814ce40772c66186c9e6addce1e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best AI driven biotech stocks to invest in. On May 22, Denali Therapeutics Inc. (NASDAQ:DNLI) halted its joint work with Biogen Inc. (NASDAQ:BIIB), around the development of BIIB122 for idiopathic Parkinson’s disease. The decision came after topline results from the Phase 2b LUMA trial showed that […]",
                "category": "company",
                "datetime": 1781173235,
                "headline": "What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names"
              },
              {
                "id": 140606619,
                "url": "https://finnhub.io/api/news?id=fd6f0d7e52511535346293ce7740de0ed5a88b8f80d6166664cd8dce90186f69",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/10/The-Logo-And-Building-For-Qualcomm.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Congresswoman Maria Elvira Salazar is buying stocks once again in 2026. Here's the new stocks she bought.",
                "category": "company",
                "datetime": 1781117187,
                "headline": "Congresswoman Who Bought No Stocks In 2025 Is Back With More 2026 Trades: Here's The Shopping List"
              },
              {
                "id": 140592936,
                "url": "https://finnhub.io/api/news?id=2403a61997d0fd34921d1cd084a2a09f77a21c88705316910c58959b7dc1174f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
                "category": "company",
                "datetime": 1781094808,
                "headline": "1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky"
              },
              {
                "id": 140595822,
                "url": "https://finnhub.io/api/news?id=ce891615efbe9fc7db1740816c434288f1c101e3136af06e6beb596251a353b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.",
                "category": "company",
                "datetime": 1781089586,
                "headline": "How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?"
              },
              {
                "id": 140580297,
                "url": "https://finnhub.io/api/news?id=f873c24975228e4610b3870636f5d54f9708bfd96651429da5faac2a63050b80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "EVERSANA®, a leading global provider of commercial services to the life sciences industry, today announced the expansion of its already leading market access offering with the appointment of Jen Norton as President, Market Access & Value. In this new role, Norton will lead the development of a dedicated, technology-first fully integrated market access business unit, uniting EVERSANA's comprehensive services to help clients navigate the complex global pricing and access landscape.",
                "category": "company",
                "datetime": 1781007360,
                "headline": "EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton"
              },
              {
                "id": 140582796,
                "url": "https://finnhub.io/api/news?id=18aaad2d908c491283b591ef2fbd7c9287c3d3f195ae2a7d68775accfab02701",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": " ",
                "category": "company",
                "datetime": 1781003739,
                "headline": "This House of Representative Just Bought Up To $375K In Biogen Stock"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 58,
            "discarded_article_count": 46
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.8,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(17.5%→10.6%)；跌縮量(近10日3日)；站上MA50；升放量(近10日3日)；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1171220,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1403990,
              "avg_vol_20": 1262960,
              "avg_vol_30": 1171220,
              "range_pct_10": 0.10587702981247801,
              "range_pct_20": 0.13332663013423163,
              "range_pct_30": 0.17505409481675127,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1987414832396988,
              "dist_to_20d_high": 0.0947114509375569,
              "down_shrink_days": 3,
              "breakout_level_20d": 219.72,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.604824639625319
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.5924287366145493,
              "turnoverUsdM": 324.98731331,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BIIB",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 184.6186,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 7.2,
            "take_profit_price": 213.6182,
            "target_multiplier": 1.9,
            "technical_strength": 1.63,
            "take_profit_percent": 7.4
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 7.184857473229099,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 7.1457,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.59
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -54.62
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.163
    },
    "kdj": {
      "d": 48.88,
      "j": -5.16,
      "k": 30.87,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 45.9
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 3674959,
      "recentSlope": -337744.1,
      "previousSlope": 233580
    },
    "rsi": 50.21,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 217.7369,
      "position": "SAR喺價上",
      "distancePct": 9.47,
      "previousTrend": "下降"
    },
    "ma50": 197.1758,
    "macd": {
      "macd": 2.8550614903093106,
      "trend": "中性偏多",
      "signal": 3.909439663791466,
      "histogram": -1.0543781734821556
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 204.056,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.26,
      "score": 6,
      "avgVolume": 1297942,
      "currentVolume": 1633841
    },
    "derived": {
      "ma20": 203.5105,
      "ma50": 197.1758,
      "prevClose": 200.36,
      "avgVolume10": 1432494,
      "avgVolume20": 1297942,
      "changePercent": -0.72,
      "avgVolumeForScore": 1297942
    },
    "ma_cross": {
      "ma20": 203.5105,
      "ma50": 197.1758,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 203.52,
      "prevMa50": 196.811,
      "spreadPct": 3.21,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 188.7807,
      "upper": 218.2403,
      "position": "中間"
    },
    "rsi_short": 21.33,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.26
    }
  }
}

{
  "close": 198.91,
  "volume": 1633841,
  "changePercent": -0.72
}